ScholarLens Back to search
2009•jOURNAL OF southwest University for NationalitiesRequires access

Cost-effectiveness analysis of Fleroxacin and Pefloxacin for impenetrate treatment of lower respiratory infection

Jing Li

Open publisher page 0 citations

Abstract

Objective:To investigate the cost-effect of Fleroxacin and Pefloxacin for impenetrate treatment of lower respiratory infection. Methods:122 cases with lower respiratory infection are selected by retrospective analysis. They are divided into 2 groups and treated with Fleroxacin and Pefloxacin, respectively. The cost-effect of two groups is analyzed and compared with each other by the statistical method and cost-effectiveness analysis. Results:The effectiveness rates of Fleroxacin and Pefloxacin are 89.83%and 87.30% respectively, there is no statistically significant difference (P0.05). The costs of two drugs are 290.63 and 36.07 yuan respectively; and their cost-efect ratios are 3.23 and 2.70, respectively. Conclusion:Pefloxacin has cost-effect advantage over Fleroxacin in the impenetrate treatment of lower respiratory infection.

About this research paper

What this paper is about

Objective:To investigate the cost-effect of Fleroxacin and Pefloxacin for impenetrate treatment of lower respiratory infection. Methods:122 cases with lower respiratory infection are selected by retrospective analysis. They are divided into 2 groups and treated with Fleroxacin and Pefloxacin, respectively. The cost-effect of two groups is analyzed and compared with each other by the statistical method and cost-effectiveness analysis. Results:The effectiveness rates of Fleroxacin and Pefloxacin are 89.83%and 87.30% respectively, there is no statistically significant difference (P0.05). The costs of two drugs are 290.63 and 36.07 yuan respectively; and their cost-efect ratios are 3.23 and 2.70, respectively. Conclusion:Pefloxacin has cost-effect advantage over Fleroxacin in the impenetrate treatment of lower respiratory infection.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate the cost-effect of Fleroxacin and Pefloxacin for impenetrate treatment of lower respiratory infection. Methods:122 cases with lower respiratory infection are selected by retrospective analysis. They are divided into 2 groups and treated with Fleroxacin and Pefloxacin, respectively. The cost-effect of two groups is analyzed and compared with each other by the statistical method and cost-effectiveness analysis. Results:The effectiveness rates of Fleroxacin and Pefloxacin are 89.83%and 87.30% respectively, there is no statistically significant difference (P0.05). The costs of two drugs are 290.63 and 36.07 yuan respectively; and their cost-efect ratios are 3.23 and 2.70, respectively. Conclusion:Pefloxacin has cost-effect advantage over Fleroxacin in the impenetrate treatment of lower respiratory infection.

Key concepts: Fleroxacin, Pefloxacin, Medicine, Significant difference, Cost-effectiveness analysis, Ampacity, Internal medicine, Cost effectiveness

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Cost-effectiveness analysis of Fleroxacin and Pefloxacin for impenetrate treatment of lower respiratory infection — Research Paper | ScholarLens